Chemomab Therapeutics (CMMB) Share-based Compensation (2018 - 2023)
Chemomab Therapeutics (CMMB) posted Share-based Compensation of $238000.0 for Q4 2023, up 83.08% on a QoQ basis from $130000.0 in Q3 2023, and up 109.7% year-over-year from $113496.3 in Q4 2022.
Chemomab Therapeutics (CMMB) Share-based Compensation (2018 - 2023) Analysis & Trends
Chemomab Therapeutics' Share-based Compensation history runs 6 years deep, the most recent figure standing at $238000.0 for Q4 2023.
- Quarterly Share-based Compensation rose 109.7% year-over-year to $238000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.5 million (up 8670.59% YoY) and the FY2025 annual result came in at $623000.0, up 0.97% from the prior year.
- Share-based Compensation was $238000.0 for Q4 2023 at Chemomab Therapeutics, up from $130000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $874000.0 in Q1 2022 and bottomed at -$2.5 million in Q4 2022.
- A 5-year average of $162200.0 and a median of $279500.0 in 2019 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2021 — Share-based Compensation tumbled 589.71% — and 2022, when it soared 1932.56%.
- Chemomab Therapeutics' Share-based Compensation stood at $89000.0 in 2019, then soared by 52.81% to $136000.0 in 2020, then tumbled by 589.71% to -$666000.0 in 2021, then plunged by 268.47% to -$2.5 million in 2022, then jumped by 109.7% to $238000.0 in 2023.
- Business Quant data shows CMMB's Share-based Compensation at $238000.0 in Q4 2023, $130000.0 in Q3 2023, and $639000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 3.20 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 87.30 Mn |
| 10 | Chemomab Therapeutics | 704.11 Mn | 693.75 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 238,000.00 |
| Dec 31, 2023 | 238,000.00 |
| Sep 30, 2023 | 130,000.00 |
| Sep 30, 2023 | 130,000.00 |
| Jun 30, 2023 | 639,000.00 |
| Jun 30, 2023 | 639,000.00 |
| Mar 31, 2023 | 484,000.00 |
| Mar 31, 2023 | 484,000.00 |
| Dec 31, 2022 | -2.45 Mn |
| Dec 31, 2022 | -2.45 Mn |
| Sep 30, 2022 | 836,000.00 |
| Sep 30, 2022 | 836,000.00 |
| Jun 30, 2022 | 761,000.00 |
| Jun 30, 2022 | 761,000.00 |
| Mar 31, 2022 | 874,000.00 |
| Mar 31, 2022 | 874,000.00 |
| Dec 31, 2021 | -666,000.00 |
| Dec 31, 2021 | -666,000.00 |
| Sep 30, 2021 | 441,000.00 |
| Sep 30, 2021 | 441,000.00 |